Erratum to clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation
Erratum

Erratum to clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation

Xueyang Hu1, Wenjun Chen2, Xiaoqiu Li1, Chenchen Zhao1, Congjun Zhang1, Fuxing Xiong1, Hongyang Wu1

1Department of Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei 230031, China;2Phase I Clinical Center, Anhui Chest Hospital, Hefei 230022, China

#These authors contributed equally to this work.

Correspondence to: Hongyang Wu, MD, PhD. Department of Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei 230031, China. Email: wuhoya1970@163.com.

doi: 10.21037/apm.2019.12.08

Erratum to: Ann Palliat Med 2019;8:525-31

Clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation

In the November 2019 issue of Annals of Palliative Medicine, the paper “Clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation” (1) by Dr. Xueyang Hu et al. was published with an error in the authorship.

The authors would like to correct and declare that the first two authors Dr. Xueyang Hu and Dr. Wenjun Chen contributed equally to this work, and being the co-first authors of this paper.

The authors regret the error and all inconveniences caused.

References

  1. Hu X, Chen W, Li X, et al. Clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation. Ann Palliat Med 2019;8:525-31. [Crossref] [PubMed]
Cite this article as: Hu X, Chen W, Li X, Zhao C, Zhang C, Xiong F, Wu H. Erratum to clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation. Ann Palliat Med 2020;9(1):120. doi: 10.21037/apm.2019.12.08

Article Options

Download Citation

Share